Hormone replacement therapy does lower total cholesterol and LDL cholesterol in most postmenopausal women, with LDL reductions in the range of roughly 7 to 20 percent depending on the formulation and route. But cholesterol is not a single number, and HRT’s effects on different lipid fractions pull in different directions. The triglyceride story, for instance, can go the opposite way with certain regimens, and the type of progestin added to estrogen matters more than many prescribers appreciate.
Why Menopause Shifts Cholesterol in the First Place
To understand what HRT is correcting, you need to know what menopause does to your lipids. As estrogen levels fall, LDL cholesterol and triglycerides climb, while HDL cholesterol changes in ways that reduce its protective qualities. These shifts happen independent of normal aging. Research tracking lipid trajectories through midlife found that the steepest increases in LDL and total cholesterol occur within about a year of the final menstrual period.1PubMed. Dyslipidemia across the menopause transition: Mechanisms, trajectories, and opportunities for cardiovascular prevention Studies comparing perimenopausal and postmenopausal women confirm that total cholesterol, LDL, and triglycerides are all higher after menopause, while HDL is lower.2PubMed. Lipid profile changes during the menopausal transition
Interestingly, the pattern is not a simple straight line upward. A large study using data from the Study of Women’s Health Across the Nation found that several lipid measures follow an inverted U-shaped trajectory: they rise in the years leading up to menopause, then actually start to decline afterward. LDL and apolipoprotein B, however, can begin rising as early as five years before the final period.3PubMed Central. Trajectories of Blood Lipids Profile in Midlife Women: Does Menopause Matter? The practical takeaway is that by the time a woman is solidly postmenopausal, her lipid profile has often shifted meaningfully toward higher cardiovascular risk. HRT enters the picture as one tool to reverse at least part of that shift.
Surgical menopause makes the case even more dramatically. Women who undergo bilateral oophorectomy lose ovarian estrogen abruptly rather than gradually, and their lipid panels can reflect this. One study found that mean triglycerides jumped from about 132 to 181 mg/dL, total cholesterol from 177 to 207 mg/dL, and LDL from 98 to 115 mg/dL after surgical menopause.4PubMed Central. Glucose Tolerance and lipid profile changes after surgical menopause
How Estrogen Lowers LDL
Estrogen’s effect on LDL cholesterol comes primarily from its action in the liver. The liver clears LDL from your bloodstream using receptors on its surface, and estrogen upregulates the production of these receptors. In animal studies, high-dose estrogen treatment increased both the protein and the genetic expression of hepatic LDL receptors several-fold. When researchers blocked estrogen receptors with drugs like tamoxifen, the LDL-lowering effect vanished, confirming that the process is estrogen-receptor dependent.5PubMed. Importance of estrogen receptors in hepatic LDL receptor regulation In plain terms, more estrogen means the liver pulls more LDL particles out of circulation.
This mechanism explains why HRT consistently lowers LDL in clinical trials. In one study of postmenopausal women with high cholesterol, adding continuous combined HRT to a healthy diet brought average LDL down from 181 mg/dL to 150 mg/dL, a drop of about 17 percent. Total cholesterol fell from 261 to 233 mg/dL, and HDL rose modestly from 51 to 54 mg/dL.6PubMed. Effects of continuous combined hormone-replacement therapy on lipid levels in hypercholesterolemic postmenopausal women A trial in perimenopausal and early postmenopausal women found that two different estrogen preparations both lowered LDL by around 8 percent and raised HDL by 6 to 8 percent compared with placebo, with the lipid changes being more pronounced in postmenopausal women than in perimenopausal women.7PubMed. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women
Oral Versus Transdermal Estrogen
The way estrogen enters your body changes which lipid fractions it affects and by how much. Oral estrogen passes through the liver first (the “first-pass effect”), which amplifies its impact on liver-made proteins and lipids. Transdermal estrogen, delivered through a patch or gel, enters the bloodstream directly and reaches the liver in lower concentrations. The differences in lipid response are clinically meaningful.
A head-to-head study comparing the two routes over several years found that both oral and transdermal estrogen reduced total cholesterol and LDL. But the oral group saw slightly higher LDL reductions (about 17 percent versus around 5 percent for the patch), and HDL dropped by roughly 9 percent with the patch while rising slightly with oral estrogen. Triglycerides, meanwhile, went in opposite directions: they fell by about 16 percent with transdermal estrogen but rose slightly with oral.8PubMed. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens Another long-term study confirmed the same pattern: transdermal estrogen dropped triglycerides by about 11 percent, while oral estrogen nudged them upward.9PubMed. Long-term effects of transdermal and oral estrogens on serum lipids and lipoproteins in postmenopausal women
If you are someone whose main lipid concern is LDL and HDL, oral estrogen tends to produce a bigger favorable shift. If your triglycerides are already elevated, transdermal estrogen may be safer and more beneficial for that specific measure.
The Triglyceride Warning
Oral estrogen’s tendency to raise triglycerides is more than a statistical footnote. It happens because estrogen stimulates the liver to produce more VLDL particles, which are triglyceride-rich.10PubMed Central. Role of Estrogens in the Regulation of Liver Lipid Metabolism For most women, the bump is modest and not dangerous. But in people who already have a genetic tendency toward high triglycerides, oral estrogen can push levels into a range that triggers acute pancreatitis, a painful and potentially life-threatening emergency.
Case reports illustrate the risk. One documented case involved severe hypertriglyceridemia and acute pancreatitis in a woman receiving intramuscular estradiol valerate for fertility treatment.11PubMed Central. Severe hypertriglyceridemia and pancreatitis following hormone replacement prior to cryothaw transfer Another case involved a transgender woman on high-dose oral estradiol whose underlying tendency toward mixed dyslipidemia was worsened by the estrogen, resulting in pancreatitis.12Clinical Medicine. Acute pancreatitis due to hypertriglyceridaemia in a transgender woman: a complication of high-dose oral oestrogen therapy? Estrogen can aggravate hypertriglyceridemia both by increasing VLDL secretion and by reducing the enzyme that breaks down triglycerides in the blood.13PubMed Central. Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction
This does not mean everyone on oral estrogen should worry about pancreatitis. The risk is concentrated in people with pre-existing hypertriglyceridemia or familial lipid disorders. But it is a good reason to have a baseline lipid panel before starting HRT and to check levels again a few months in, especially if you are using an oral formulation.
Beyond the Numbers on HDL
HDL is often called “good cholesterol,” but how well HDL works matters at least as much as how much of it you have. Researchers now focus on a measure called cholesterol efflux capacity, which captures how effectively your HDL particles pull cholesterol out of artery walls. This turns out to be a better predictor of heart disease risk than simply counting HDL particles or measuring HDL-cholesterol concentration.14PubMed. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity
This is where HRT’s effect on HDL gets complicated. Transdermal estradiol given to perimenopausal women actually reduced HDL cholesterol efflux capacity compared with placebo, even while improving other cardiovascular risk factors like blood-vessel function.15PubMed Central. Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors A review of estradiol and HDL function confirmed that the route of administration appears significant in determining how HDL quality responds.16PubMed Central. Estradiol and HDL Function in Women – A Partnership for Life So an HDL number that looks stable or slightly improved on a standard blood test may mask more nuanced changes in how well that HDL is actually protecting your arteries.
Lipoprotein(a) and the Atherogenic Profile
One of HRT’s most notable lipid effects involves lipoprotein(a), or Lp(a). This is a genetically determined particle that drives plaque formation and is notoriously hard to budge with diet or most medications. HRT lowers it substantially. Estrogen replacement alone reduced Lp(a) by about 37 percent in one study, though adding a progestin partly blunted that benefit.17JAMA Internal Medicine. Effect of Hormone Replacement Therapy on Lipoprotein(a) and Lipid Levels in Postmenopausal Women: Influence of Various Progestogens and Duration of Therapy In the large Heart and Estrogen/Progestin Replacement Study, women taking HRT had lower Lp(a) levels than those not on therapy.18PubMed Central. Lipoprotein(a), Hormone Replacement Therapy and Risk of Future Cardiovascular Events
The broader atherogenic picture is also favorable. A randomized trial found that HRT significantly reduced Lp(a), apolipoprotein B, total cholesterol, LDL, and the atherogenic ratios of total cholesterol to HDL and LDL to HDL at three months. The drop in Lp(a) correlated with the rise in estradiol, reinforcing that the estrogen itself was driving the change.19PubMed. Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women The PEPI trial, one of the landmark hormone-therapy studies, confirmed that Lp(a) changes tracked alongside changes in LDL and apolipoprotein B across diverse subgroups of women.20PubMed. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration – Section: METHODS AND RESULT
HRT also improved the broader apolipoprotein profile in a study of postmenopausal Japanese women, with significant decreases in apolipoprotein B and increases in apolipoprotein A-I across all genotypes tested.21The Journal of Clinical Endocrinology & Metabolism. Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women In plain terms, the particles that build plaque went down, and the particles that help clear it went up.
How Progestins Complicate the Picture
Most postmenopausal women with an intact uterus take a progestin alongside estrogen to prevent endometrial overgrowth. This is important for safety but comes at a lipid cost. Progestins tend to lower HDL and partially offset estrogen’s LDL-lowering effect. The degree of offset depends on which progestin is used. A review focused specifically on progestins in HRT found that this is one of the most important variables for assessing cardiovascular risk in women on combination therapy.22PubMed Central. The effects of progesterones on blood lipids in hormone replacement therapy
Micronized progesterone, which is chemically identical to the body’s own progesterone, generally has the mildest effect on lipids. Synthetic progestins like medroxyprogesterone acetate or norethindrone are more likely to push HDL down and dampen the Lp(a) benefit. The estrogen-alone reduction in Lp(a) was about 37 percent, but adding a progestin attenuated that effect.17JAMA Internal Medicine. Effect of Hormone Replacement Therapy on Lipoprotein(a) and Lipid Levels in Postmenopausal Women: Influence of Various Progestogens and Duration of Therapy If you have a choice, the type of progestin in your HRT regimen is worth discussing with your doctor specifically for its lipid effects.
HRT Is Not a Statin Substitute
While HRT lowers LDL, it does not lower it as much as a statin. A direct comparison study in postmenopausal women with coronary artery disease and high cholesterol found that simvastatin cut LDL by 45 percent, HRT alone cut it by 20 percent, and the combination achieved a 46 percent reduction. None of the women on HRT alone reached the aggressive LDL targets recommended for heart disease patients.23PubMed. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease The conclusion from researchers comparing the two approaches has been clear: for women who need serious cholesterol lowering, statins are the first-line therapy, though HRT can add other cardiovascular benefits on top.24PubMed. The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women
That said, HRT’s lipid effects are a genuine bonus rather than its primary purpose. A woman taking HRT for hot flashes, sleep disruption, or bone protection gets the LDL and Lp(a) reductions as side benefits. For a woman whose LDL is borderline and who also needs menopausal symptom relief, HRT might be enough to nudge her lipids into a better range without adding another medication.
When You Start Matters for Your Heart
The relationship between HRT, cholesterol, and actual cardiovascular outcomes has been one of the most debated topics in medicine. The Women’s Health Initiative trial, published in 2002, appeared to show that HRT caused more harm than good, and HRT prescriptions plummeted.25PubMed Central. The Controversial History of Hormone Replacement Therapy Later reanalysis introduced the “timing hypothesis”: HRT started close to menopause onset may reduce coronary disease and overall mortality, while starting it ten or more years after menopause may not help and could increase risk.26European Heart Journal Open. Hormone replacement therapy and cardiovascular risk in postmenopausal women
More recent data add nuance. A large UK Biobank analysis found that HRT use was associated with modestly elevated risk of atherosclerotic cardiovascular disease overall, with the size of the risk depending on factors like age at menarche and age at menopause. Women with late menopause who used HRT showed a more substantial risk increase than those with intermediate menopause timing.27PubMed Central. Elevated cardiovascular risk associated with hormone replacement therapy: A comprehensive analysis of reproductive factors and atherosclerotic cardiovascular disease outcomes in the UK Biobank cohort The point is that favorable lipid changes on a blood test do not automatically translate into fewer heart attacks, because HRT also affects clotting, inflammation, and blood vessel function in ways that can cut both directions.
Genetic Variation in Lipid Response
Not every woman’s cholesterol responds to HRT in the same way, and genetics is one reason. Researchers have found that variations in estrogen receptor genes affect how much LDL drops on therapy. One study identified a specific polymorphism in the ESR1 gene that was associated with LDL-cholesterol levels in women taking HRT, and a haplotype in the ESR2 gene that was linked to both total cholesterol and LDL in the same group.28PubMed. Are polymorphisms in oestrogen receptors genes associated with lipid levels in response to hormone therapy? Separately, research in Japanese postmenopausal women showed that while HRT improved lipid profiles across all genotypes of a hepatic lipase gene variant, the magnitude of the response differed by genotype.21The Journal of Clinical Endocrinology & Metabolism. Effects of Hormone Replacement Therapy and Hepatic Lipase Polymorphism on Serum Lipid Profiles in Postmenopausal Japanese Women
Genetic testing for HRT lipid response is not standard clinical practice and probably will not be anytime soon, but these findings help explain why two women on identical regimens can see quite different changes on their next blood panel.
Transgender Women on Estrogen Therapy
Transgender women taking estrogen as part of gender-affirming hormone therapy offer a different window into estrogen’s lipid effects, because they are starting from a male-range lipid baseline. A systematic review and meta-analysis found that by five years on therapy, transgender women saw total cholesterol rise by about 14 mg/dL and LDL rise by about 7 mg/dL, with no notable change in HDL or triglycerides.29PubMed Central. Changes in Blood Lipids Following Initiation of Gender Affirming Hormone Therapy: A Systematic Review and Meta-Analysis A smaller imaging-based study found the opposite pattern in transgender women: total and LDL cholesterol decreased significantly, while triglycerides increased minimally.30Journal of Clinical & Translational Endocrinology. The effects of gender-affirming hormone therapy on myocardial, hepatic, pancreatic lipid content, body fat distribution and other cardiometabolic risk factors
The inconsistency across studies is partly explained by differences in estrogen formulations, doses, concomitant anti-androgen use, and follow-up length. It is also a reminder that estrogen’s lipid effects depend heavily on the hormonal environment it enters. Suppressing testosterone while adding estrogen creates a different metabolic context than simply replacing lost estrogen in a postmenopausal woman.
Phytoestrogens as a Milder Alternative
Women who cannot or prefer not to take HRT sometimes turn to plant-based estrogen-like compounds, particularly soy isoflavones and red clover extracts. These are far weaker than pharmaceutical estrogen, but they do have measurable lipid effects. In one trial, postmenopausal women taking soy or red clover supplements had significantly lower triglycerides, total cholesterol, and LDL, and higher HDL, compared to a control group at all measured time points. The two phytoestrogen sources performed similarly to each other.31PubMed Central. Impact of Phytoestrogens on Serum Lipids in Postmenopausal Women
The magnitude of change with phytoestrogens is smaller than with HRT, and the evidence base is thinner. They are not going to replace a statin or even pharmaceutical HRT for someone who needs significant cholesterol lowering. But for a woman with mildly unfavorable lipid shifts after menopause who wants to avoid prescription hormones, they represent a middle ground with some data behind it. As with HRT, individual responses vary, and baseline lipid levels should be tracked.